This book explores the application of pharmacogenomics in optimizing cancer chemotherapy regimens. It covers genetic predictors of drug response, resistance mechanisms, and toxicity in various cancers. The book emphasizes personalized chemotherapy plans to improve survival rates and reduce side effects. Targeted at oncologists and pharmacogenomic researchers, it advances precision oncology through genetic profiling.
Brandon Bailey applies pharmacogenomics to personalize cancer chemotherapy treatments for skin cancers such as melanoma and basal cell carcinoma. His research focuses on identifying genetic markers that predict patient responses to chemotherapeutic agents, enhancing treatment efficacy and minimizing toxicity. Brandon has authored numerous studies on integrating pharmacogenomic testing into chemotherapy protocols for dermatological oncology. He also offers guidelines for clinicians to adopt pharmacogenomic strategies in cancer chemotherapy, promoting personalized and effective dermatological oncology care through genetic-informed therapies.